|Bid||6.52 x 800|
|Ask||6.64 x 800|
|Day's Range||6.52 - 6.89|
|52 Week Range||6.45 - 19.00|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.25|
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 6.25% and 0.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Pipeline rapidly advancing with three clinical trials planned to initiate by early 2019, including a SPR994 Phase 3 initiation around year-end 2018 CAMBRIDGE, Mass., Nov. 08,.
Spero Therapeutics, Inc. (SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections, today announced results from preclinical IND-enabling studies of SPR720, an oral antimicrobial agent being developed for the treatment of pulmonary non-tuberculous mycobacterial (NTM) infections. SPR720 was assessed in a series of non-clinical studies, including IND-enabling 28- and 31-day GLP toxicology studies in non-human primates and rats, respectively, and safety pharmacology studies.
To keep up with the rising demand for short-term rentals in U.S. cities and compete with the home-sharing giant Airbnb, travel booking site Expedia has picked up a pair of venture-backed hospitality startups, Pillow and ApartmentJet. Employees of both companies will join Expedia . "Acquiring Pillow and ApartmentJet will help unlock urban growth opportunities that, over time, will contribute to HomeAway's ability to add an even broader selection of accommodations to its marketplace and marketplaces across Expedia Group brands, ensuring travelers always find the perfect place to stay," the company explained in a statement.
Expedia Group (EXPE) continues to benefit from the robust performance of HomeAway, Brand Expedia, Expedia Partner Solutions and Hotels.com in third-quarter 2018.
Expedia Group Inc saw major growth in its vacation rental business HomeAway and higher travel bookings in the third quarter, helping it to beat Wall Street's profit estimates on Thursday. Expedia said customers spent 24 percent more on HomeAway bookings and that the business, which competes with Airbnb, is headed for strong revenue and profit growth this year. Amobi, however, warned that the fourth quarter may not be as strong as the third and a key thing to watch would be whether Expedia is able to maintain this type of growth trajectory.
Analysts had predicted $3.10 a share, according to data compiled by Bloomberg. Expedia, which owns travel aggregator websites like Hotels.com, Hotwire.com and CarRentals.com, is starting to see the benefits of buying HomeAway three years ago. Expedia paid $3.9 billion in 2015 for the vacation-home rental site in a power play to rival upstart Airbnb Inc. Along with Booking Holdings Inc., the three have been battling to woo travelers and go beyond typical vacation packages to expand offerings in people’s homes in cities.
In a world where superbugs are overpowering various antibiotic drugs, threatening millions of lives, Massachusetts biotechs are fighting hard to ensure the bugs don't become the industry's kryptonite.
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Spero Therapeutics, Inc. (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, announced today that SPR206, a product candidate within Spero’s Potentiator Platform, has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration for the treatment of complicated urinary tract infections (cUTI) and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP). “We are pleased that the FDA recognized the potential of SPR206’s novel approach to treat multidrug-resistant Gram-negative infections and provided it with QIDP status,” said Ankit Mahadevia, M.D., CEO of Spero Therapeutics.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Sep. 27) Edwards Lifesciences Corp (NYSE: EW ) Applied Genetic ...
Spero Therapeutics, Inc. (SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company focused on developing and commercializing novel antibiotics to treat multi-drug resistant bacterial infections, today reported positive results from a final analysis of its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of SPR994, its investigational oral carbapenem product candidate designed for the treatment of Gram-negative infections. The study was conducted in healthy volunteers to assess the safety, tolerability and pharmacokinetics of SPR994. Dose escalation within the MAD portion of the Phase 1 clinical trial demonstrated that 600 mg of SPR994 provides greater drug exposure than was observed in the first dosing cohort of 300 mg while maintaining a favorable safety profile.
CAMBRIDGE, Mass., Sept. 25, 2018 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.
Spero Therapeutics is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections. Spero is advancing SPR994, a carbapenem-class antibiotic, which is designed to be the first broad-spectrum oral antibiotic for use in adults to treat MDR Gram-negative infections. The product candidates are two IV-administered agents, SPR741 and SPR206, designed to treat MDR Gram-negative infections in the hospital setting.
Every investor in Spero Therapeutics Inc (NASDAQ:SPRO) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usually see insiders owning sharesRead More...
Consumer Reports has no financial relationship with advertisers on this site. Internet-connected smart locks replace or augment your property’s existing deadbolt and give you the ability to create access codes (for use with a keypad that’s connected to the lock) and electronic keys (where a smartphone app acts as the key).